Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation | Zendy

Frank J. Accurso | Zendy; Steven M. Rowe | Zendy; John P. Clancy | Zendy; Michael Boyle | Zendy; Jordan Dunitz | Zendy; Peter R. Durie | Zendy; Scott D. Sagel | Zendy; Douglas B. Hornick | Zendy; Michael W. Konstan | Zendy; Scott H. Donaldson | Zendy; Richard B. Moss | Zendy; Joseph M. Pilewski | Zendy; Ronald C. Rubenstein | Zendy; Ahmet Uluer | Zendy; Moira L. Aitken | Zendy; Steven D. Freedman | Zendy; Lynn M. Rose | Zendy; Nicole Mayer-Hamblett | Zendy; Qunming Dong | Zendy; Jiuhong Zha | Zendy; Anne J. Stone | Zendy; Eric R. Olson | Zendy; Claudia L. Ordoñez | Zendy; Preston W. Campbell | Zendy; Melissa A. Ashlock | Zendy; Bonnie W. Ramsey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutation

Author(s) -

Frank J. Accurso,

Steven M. Rowe,

John P. Clancy,

Michael Boyle,

Jordan Dunitz,

Peter R. Durie,

Scott D. Sagel,

Douglas B. Hornick,

Michael W. Konstan,

Scott H. Donaldson,

Richard B. Moss,

Joseph M. Pilewski,

Ronald C. Rubenstein,

Ahmet Uluer,

Moira L. Aitken,

Steven D. Freedman,

Lynn M. Rose,

Nicole Mayer-Hamblett,

Qunming Dong,

Jiuhong Zha,

Anne J. Stone,

Eric R. Olson,

Claudia L. Ordoñez,

Preston W. Campbell,

Melissa A. Ashlock,

Bonnie W. Ramsey

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0909825

Subject(s) - cystic fibrosis , medicine , placebo , ivacaftor , cystic fibrosis transmembrane conductance regulator , adverse effect , gastroenterology , anesthesia , urology , pathology , alternative medicine

A new approach in the treatment of cystic fibrosis involves improving the function of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a CFTR potentiator, has been shown to increase the activity of wild-type and defective cell-surface CFTR in vitro.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research